For example, using proteasome inhibitor and/or targeting key elements of the UPS-mediated GABAAα1 turnover (for example, SYVN1) could offer a new strategy for treating GABAergic deficits often seen in ASD and related CNS disorders. This evidence concerns the gene SYVN1 and central nervous system disorder.